These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 28818518

  • 1. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
    Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM.
    Lancet Gastroenterol Hepatol; 2017 Oct; 2(10):716-726. PubMed ID: 28818518
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM, ELATIVE Study Investigators’ Group, ELATIVE Study Investigators' Group.
    N Engl J Med; 2024 Feb 29; 390(9):795-805. PubMed ID: 37962077
    [Abstract] [Full Text] [Related]

  • 6. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, Bonder A, Hirschfield GM, Levy C, Vierling J, Jones D, Tailleux A, Staels B, Megnien S, Hanf R, Magrez D, Birman P, Luketic V.
    J Hepatol; 2021 Jun 29; 74(6):1344-1354. PubMed ID: 33484775
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
    Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Böhm O, Shapiro D.
    Gastroenterology; 2015 Apr 29; 148(4):751-61.e8. PubMed ID: 25500425
    [Abstract] [Full Text] [Related]

  • 8. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
    Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R.
    N Engl J Med; 2018 Jun 07; 378(23):2171-2181. PubMed ID: 29874528
    [Abstract] [Full Text] [Related]

  • 9. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
    Schramm C, Wedemeyer H, Mason A, Hirschfield GM, Levy C, Kowdley KV, Milkiewicz P, Janczewska E, Malova ES, Sanni J, Koo P, Chen J, Choudhury S, Klickstein LB, Badman MK, Jones D.
    JHEP Rep; 2022 Nov 07; 4(11):100544. PubMed ID: 36267872
    [Abstract] [Full Text] [Related]

  • 10. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, Storey J, Dukes GE, Corrigan M, Oude Elferink RP, Beuers U, Hirschfield GM, Jones DE.
    Lancet; 2017 Mar 18; 389(10074):1114-1123. PubMed ID: 28187915
    [Abstract] [Full Text] [Related]

  • 11. Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
    Mayo MJ, Vierling JM, Bowlus CL, Levy C, Hirschfield GM, Neff GW, Galambos MR, Gordon SC, Borg BB, Harrison SA, Thuluvath PJ, Goel A, Shiffman ML, Swain MG, Jones DEJ, Trivedi P, Kremer AE, Aspinall RJ, Sheridan DA, Dörffel Y, Yang K, Choi YJ, McWherter CA.
    Aliment Pharmacol Ther; 2024 Jan 18; 59(2):186-200. PubMed ID: 37904314
    [Abstract] [Full Text] [Related]

  • 12. Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis.
    Caines A, Trudeau S, Gordon SC.
    Expert Opin Pharmacother; 2024 Aug 18; 25(11):1517-1523. PubMed ID: 39107982
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study.
    Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, MacConell L, Shapiro D.
    Lancet Gastroenterol Hepatol; 2019 Jun 18; 4(6):445-453. PubMed ID: 30922873
    [Abstract] [Full Text] [Related]

  • 14. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    Kowdley KV, Vuppalanchi R, Levy C, Floreani A, Andreone P, LaRusso NF, Shrestha R, Trotter J, Goldberg D, Rushbrook S, Hirschfield GM, Schiano T, Jin Y, Pencek R, MacConell L, Shapiro D, Bowlus CL, AESOP Study Investigators.
    J Hepatol; 2020 Jul 18; 73(1):94-101. PubMed ID: 32165251
    [Abstract] [Full Text] [Related]

  • 15. Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis.
    Kremer AE, Mayo MJ, Hirschfield GM, Levy C, Bowlus CL, Jones DE, Johnson JD, McWherter CA, Choi YJ.
    Hepatology; 2024 Jul 01; 80(1):27-37. PubMed ID: 38117036
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.
    Jacob S, Veenstra-VanderWeele J, Murphy D, McCracken J, Smith J, Sanders K, Meyenberg C, Wiese T, Deol-Bhullar G, Wandel C, Ashford E, Anagnostou E.
    Lancet Psychiatry; 2022 Mar 01; 9(3):199-210. PubMed ID: 35151410
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
    Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M, Austrian/German NAFLD-norUDCA study group.
    Lancet Gastroenterol Hepatol; 2019 Oct 01; 4(10):781-793. PubMed ID: 31345778
    [Abstract] [Full Text] [Related]

  • 19. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
    Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D, POISE Study Group.
    N Engl J Med; 2016 Aug 18; 375(7):631-43. PubMed ID: 27532829
    [Abstract] [Full Text] [Related]

  • 20. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M.
    Lancet Oncol; 2017 Jul 18; 18(7):904-916. PubMed ID: 28576675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.